Hansifei

1、 Educational Experience

2010–2014: PhD in Pharmaceutical Sciences, Monash University, Australia (advisor: Prof Christopher Porter and A/Prof Natalie Trevaskis)

2006–2009: Master in Pharmaceutics, Shanghai Institute of Material Medical, Chinese Academy of Sciences, China (advisor: Prof Yong Gan)

2002–2006: B.S. in Chemistry, Nanjing University, China

2、Working Experience

2022-Present: Lab head, Department of Pharmacology, School of Pharmacy, China Pharmaceutical University

2017-2021: NHMRC Early Career Fellow, Monash Institute of Pharmaceutical Sciences, Monash University, Australia

2014-2017: Postdoc research fellow, Monash institute of Pharmaceutical Sciences, Monash University, Australia

1. S Han, T Quach, L Hu, SF Lim, D Zheng, NJ Leong, G Sharma, D Bonner, JS Simpson, NL Trevaskis, CJH Porter. Increasing linker chain length and intestinal stability enhances lymphatic transport and lymph node exposure of triglyceride mimetic prodrugs of a model immunomodulator mycophenolic acid. Molecular Pharmaceutics, 2023, in press

2. T Quach, L Hu, S Han*, SF Lim, D Senyschyn, P Yadav, NL Trevaskis, JS Simpson, CJH Porter*. Triglyceride-mimetic Prodrugs of Buprenorphine Enhance Oral Bioavailability via Promotion of Lymphatic Transport. Front. Pharmacology, (2022) doi: 10.3389/fphar.2022.879660

3.Z Fu, S Li, S Han, C Shi, Y Zhang. Antibody drug conjugate: the ‘biological missile’ for targeted cancer therapy. Signal Transduction and Targeted Therapy, 7 (2022), 93

4.S Han*, L Mei, T Quach, CJH Porter, NT Trevaskis*. Lipophilic Conjugates of Drugs: A Tool to Improve Drug Pharmacokinetic and Therapeutic Profiles. Pharm. Research, 38 (2021):1497-1518

5.R Kochappan, E Cao, S Han*, L Hu, T Quach, D Senyschyn, VI Ferreira, G Lee, S Lim, C Nowell, D Bonner, J Mintern, JS Simpson, NL Trevaskis*, CJH Porter*. Targeted delivery of mycophenolic acid to the mesenteric lymph node using a triglyceride mimetic prodrug approach enhances gut-specific immunomodulation in mice. J. Control. Release, 332 (2021), 636-651

6.S Han, T Quach, L Hu, SF Lim, Gracia, NL Trevaskis, JS Simpson, CJH Porter. The impact of conjugation position and linker chemistry on the lymphatic transport of a series of glyceride and phospholipid mimetic prodrugs. J. Pharm. Sci. 110 (2021), 489-499

7.G Lee, S Han, I Inocencio, E Cao, J Hong, ARJ Phillips, JA Windsor, CJH Porter, NL Trevaskis. Lymphatic uptake of liposomes after intraperitoneal administration primarily occurs via the diaphragmatic lymphatics and is dependent on liposome surface properties. Mol. Pharmaceutics. 16 (2019), 4987-4999

8.S Han, L Hu, Gracia, T Quach, JS Simpson, GA Edwards, NL Trevaskis, CJH Porter. Lymphatic Transport of a Triglyceride Mimetic Prodrug in a Large Animal Model: Studies in Greyhound Dogs. Mol. Pharmaceutics. 13 (2016): 3351-3361 (Faculty 1000 recommended article)

9.L Hu#, T Quach# S Han#, SF Lim, NL Trevaskis, JS Simpson, CJH Porter. Glyceride-Mimetic Prodrugs Incorporating Self-Immolative Spacers Promote Lymphatic Transport, Avoid First-Pass Metabolism, and Enhance Oral Bioavailability. Angew Chem Int Ed Engl., 55 (2016), 13700-13705 (Frontispiece )

10.S Han, T Quach, L Hu, A Wahab, WN Charman, VJ Stella, NL Trevaskis, JS Simpson, CJH Porter. Targeted delivery of a model immunomodulator to the lymphatic system: Comparison of alkyl ester versus triglyceride mimetic lipid prodrug strategies. J. Control. Release, 177 (2014), 1-10 (Cover)

National Health and Medical Research Council (Australia) Early Career Fellow Grant: GNT1127889, A biomimetic prodrug platform to enable oral bioavailability and target lymphatic disease, 2017-2021

Dr. Sifei Han joined the China Pharmaceutical University and started a new research group (co-led with Dr Luojuan Hu) in late 2022. Before that, Sifei worked with Prof Chris Porter and A/Prof Natalie Trevaskis at Monash Institute of Pharmaceutical Sciences, Monash University (Australia) for 7 years focusing on lymphatic drug delivery. Sifei co-led the biopharm team and developed a lymph targeting prodrug strategy that improves drug delivery to pharmacological targets in the lymphatic system, and/or that enhances systemic exposure of drugs such as testosterone and buprenorphine where oral bioavailability is limited due to substantial first-pass metabolism. The technology platform consists of >10 patent families and has been licensed to a clinical stage biotech company PureTech Health (Boston), and sublicensed to Boehringer Ingelheim. A Phase 1 clinical study of LYT-300 (oral allopregnanolone) based on the technology was successfully finished at the end of 2022 and a Phase 2a, proof-of-concept clinical trial is starting in 2023.